Skp2 has attracted increasing attention as an ideal antitumor drug target, and some small molecule inhibitors of Skp2 have been reported in the literature, such as SMIP004(Skp2)39, 6-O-angeloylplenolin (Skp1-Skp2)40, C1, C20(Skp2-p27)41, M1(Skp2-p300)42, NSC681152 (Skp2-Cks1), Compound 22d(Skp2-Cks1)25, etc. Most of these small molecule inhibitors act on the Skp1/Skp2-Cks1-p27 axis, thereby triggering intracellular signaling and inhibiting the growth and proliferation of tumor cells. The gene discussed is SKP1; the disease is neoplasm.